Abreos Biosciences, Inc.

San Diego, CA 92122

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $2.24MM
First Award Date 04/15/14
Most Recent Award Date 09/05/17

Key Personnel

Last Name Name Awards Contact
MESSMER BRADLEY T MESSMER 8
MARTINEZ-HACKERT ERIK MATTHIAS MARTINEZ-HACKERT 1

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/05/17 - 08/31/18

Abstract Rituximab is a monoclonal antibody (mAb) among the top 10 best- selling drugs, with global sales estimated to exceed $7B in 2015. Rituximab is indicated to treat conditions including chronic lymphocytic leukemia (CLL), B- cell non- Hodgkin's lymphoma, and various autoimmune disorders. Population ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/01/17 - 08/31/18

Abstract Viruses have significant commercial application as vectors for gene and cell therapy, as well as vaccines for cancer treatment and infectious diseases. The purification of commercial viruses is a major area of bioprocess development. Current methods are mostly based on filtration and chromatography, both of which scale poorly and requir...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/25/15 - 03/24/16

DESCRIPTION (provided by applicant) Cachexia is a major cause of suffering and death among patients with late stage cancers and the current treatment options are limited and ineffective. We have identified a novel Activin A inhibitory protein, Cryptic, that can potentially eliminate the muscle wasting activity of Activin in cachexia. Activin A ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Bone loss and fragility from osteoporosis afflict more than 200 million people worldwide, including at least 10 million Americans. Current osteoporosis treatments are significantly deficient: most fail to reverse bone loss and/or have adverse effects that prohibit their long-term use. New therapeutic approac...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 03/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Bacterial endotoxins, namely lipopolysaccharide (LPS), are common contaminants of many pharmaceutical, medical device, and food products that can elicit very strong immune responses in people and animals, sometimes resulting in septic shock. As such, monitoring for endotoxin in medical and food products is es...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-13-327
Budget: 01/01/15 - 06/30/15

DESCRIPTION (provided by applicant): Proteomics studies have the power to deliver pivotal new insight into cancer cells, biomarkers, and host responses. Unlike genomics, however, the field of proteomics has been constrained by a lack of simple and affordable analytical tools. Massively multiplex proteomic analysis methods remain expensive, cumb...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 09/23/14 - 08/31/15

DESCRIPTION (provided by applicant): Monoclonal antibodies (mAb) are used to treat a variety of cancers and other diseases. Dosing is typically based on body surface area, but population pharmacokinetic (PK) data suggests considerable variation across patients. Furthermore, there is growing evidence that patients with low final trough levels of ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 04/15/14 - 10/14/14

DESCRIPTION (provided by applicant): Monoclonal antibodies (mAb) are valuable therapeutics for treating cancer and other diseases, but their high cost makes them attractive targets for counterfeiting or illegal distribution. Numerous cases have occurred both in the US and worldwide and the complexity of the pharmaceutical distribution network ma...